

*AMENDMENTS TO THE CLAIMS*

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. - 40. (Canceled).

41. (Currently Amended) A method of preparing dual specificity lymphocytes ~~having dual specificity~~ comprising:

(i) contacting lymphocytes with a cell that is allogeneic to one or more the lymphocytes, thereby selecting for lymphocytes comprising an endogenous receptor reactive with the allogeneic cell; and

(ii) transducing the lymphocytes comprising the endogenous receptor reactive with the allogeneic cell with a chimeric receptor gene, said gene encoding a chimeric receptor, which is reactive with a tumor antigen, thereby producing dual specificity lymphocytes.

42. - 93. (Canceled)

94. (New) The method of claim 41 comprising transducing the lymphocytes comprising the endogenous receptor reactive with the allogeneic cell with a retroviral vector comprising the chimeric receptor gene.

95. (New) The method of claim 94, wherein the chimeric receptor comprises a single chain Fv receptor.

96. (New) The method of claim 95, wherein the chimeric receptor is Mov- $\gamma$ .

97. (New) The method of claim 41, wherein the tumor antigen is an ovarian tumor antigen.

98. (New) The method of claim 97, wherein the ovarian tumor antigen is folate binding protein (FBP).

99. (New) The method of claim 41, wherein the dual specificity lymphocytes are T lymphocytes.

100. (New) The method of claim 99, wherein the dual specificity T lymphocytes are human T lymphocytes.

101. (New) The method of claim 100, wherein the human T lymphocytes are lymphocytes isolated from a human.

102. (New) The method of claim 101, wherein the human comprises an ovarian cancer, melanoma, or colon cancer.

103. (New) The method of claim 41, wherein the cell is a peripheral blood mononuclear cell (PBMC), a splenocyte, a dendritic cell, or a B cell.

104. (New) The method of claim 103, comprising co-culturing the lymphocytes with allogeneic cells at a allogeneic cell:lymphocyte ratio that is about 2:1 to about 5:1.

105. (New) The method of claim 41 further comprising contacting the lymphocytes with the cell that is allogeneic to the lymphocytes after transducing the lymphocytes with a chimeric receptor gene.

106. (New) The method of claim 41, further comprising expanding the dual specificity lymphocytes in IL-2 containing media.

107. (New) The method of claim 41, further comprising expanding the dual specificity lymphocytes by a Rapid Expansion Protocol (REP) comprising co-culturing the dual specificity lymphocytes with allogeneic PBMC in culture medium comprising OKT-3 and IL-2.

108. (New) A composition comprising a population of cells comprising the lymphocytes prepared by the method of claim 41 and the cell that is allogeneic to the lymphocytes.

109. (New) The composition of claim 108, wherein the population of cells consists essentially of the dual specificity lymphocytes and the allogeneic cell.